4.6 Review

Epigenome-wide association studies: current knowledge, strategies and recommendations

Journal

CLINICAL EPIGENETICS
Volume 13, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13148-021-01200-8

Keywords

Epigenetics; Methylation; EWAS; ChAMP; Complex diseases; Bioinformatics

Ask authors/readers for more resources

The interaction between genetic and environmental factors drives the development of complex diseases, with the role of the epigenome in disease pathophysiology gaining attention. Epigenome-wide association studies (EWASes) investigating the association between phenotype and epigenetic variants, particularly DNA methylation, have increased in number in recent years due to advancements in technology. Studies focusing on methylation data in blood samples have been recommended as a cost-effective approach, with novel areas of EWAS analysis expanding to include longitudinal study designs and statistical deconvolution for identifying cell-specific differential methylation.
The aetiology and pathophysiology of complex diseases are driven by the interaction between genetic and environmental factors. The variability in risk and outcomes in these diseases are incompletely explained by genetics or environmental risk factors individually. Therefore, researchers are now exploring the epigenome, a biological interface at which genetics and the environment can interact. There is a growing body of evidence supporting the role of epigenetic mechanisms in complex disease pathophysiology. Epigenome-wide association studies (EWASes) investigate the association between a phenotype and epigenetic variants, most commonly DNA methylation. The decreasing cost of measuring epigenome-wide methylation and the increasing accessibility of bioinformatic pipelines have contributed to the rise in EWASes published in recent years. Here, we review the current literature on these EWASes and provide further recommendations and strategies for successfully conducting them. We have constrained our review to studies using methylation data as this is the most studied epigenetic mechanism; microarray-based data as whole-genome bisulphite sequencing remains prohibitively expensive for most laboratories; and blood-based studies due to the non-invasiveness of peripheral blood collection and availability of archived DNA, as well as the accessibility of publicly available blood-cell-based methylation data. Further, we address multiple novel areas of EWAS analysis that have not been covered in previous reviews: (1) longitudinal study designs, (2) the chip analysis methylation pipeline (ChAMP), (3) differentially methylated region (DMR) identification paradigms, (4) methylation quantitative trait loci (methQTL) analysis, (5) methylation age analysis and (6) identifying cell-specific differential methylation from mixed cell data using statistical deconvolution.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available